6 completed, 5 terminated. 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 6, Terminated 5 |
Follow pozanicline: new trials by email Literature Review of pozanicline trials Research Report on pozanicline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of ABT-089 on Smoking Abstinence Symptoms and Reward ABT-089, Placebo - Nicotine Addiction | Phase 2 | Terminated | University of Pennsylvania | 17 | 2013-03-01 | 2014-10-29 |
| A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study ABT-089 - Alzheimer's Disease | Phase 2 | Terminated | Abbott | 63 | 2009-01-01 | 2011-09-02 |
| Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) ABT-089 - Attention-Deficit/Hyperactivity Disorder | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 117 | 2008-05-01 | 2013-01-21 |
| Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) ABT-089, Placebo - Attention-Deficit/Hyperactivity Disorder | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 160 | 2008-03-01 | 2013-01-18 |
| Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) ABT-089, placebo - Attention-Deficit/Hyperactivity Disorder | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 121 | 2008-03-01 | 2013-01-18 |
| A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) ABT-089 - Attention-Deficit/Hyperactivity Disorder | Phase 2 | Terminated | Abbott | 283 | 2007-11-01 | 2011-08-23 |
| Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease ABT-089, placebo - Alzheimer's Disease | Phase 2 | Terminated | Abbott | 337 | 2007-11-01 | 2011-08-23 |
| A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) ABT-089, atomoxetine, placebo - Attention-Deficit/Hyperactivity Disorder | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 278 | 2007-09-01 | 2013-01-29 |
| A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD) ABT-089 - Attention Deficit Hyperactivity Disorder | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 141 | 2007-02-01 | 2013-01-18 |
| A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) ABT-089, Placebo - Attention-Deficit/Hyperactivity Disorder | Phase 2 | Completed | Abbott | 221 | 2006-10-01 | 2011-10-18 |
| A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease ABT-089 - Alzheimer's Disease | Phase 2 | Terminated | Abbott | 64 | 2003-07-01 | 2006-09-04 |
Attention Deficit Disorder with Hyperactivity (7) · Alzheimer Disease (3) · Dementia (1) · Smoking (1) · Tobacco Use Disorder (1)
AbbVie (prior sponsor, Abbott) (5) · Abbott (5) · University of Pennsylvania (1)
United States (11)
Laura Gault, MD, PhD, MD (2) · Caryn Lerman, PhD (1) · Earle Bain (1) · Earle Bain, MD (1) · Katherine A Tracy, M.D. (1) · Laura Gault (1) · Laura Gault, M.D., Ph.D. (1) · Laura Gault, MD,PhD (1) · Robert Lenz (1) · Robert Lenz, MD, PhD (1)